Disclosure notice

As a result of the preferential rights issue in Follicum AB ("Follicum") in October 2017, the holding of the shareholder, Lund University Bioscience AB's has decreased to less than ten percent of votes and equity. 

Lund University Bioscience AB is one of the main shareholders in Follicum. As a result of the recently completed preferential share issue, in which 10,670,114 new shares were issued, Lund University Bioscience AB's ownership has decreased from 14.5 percent of votes and equity to 8.7 percent of votes and equity. Following the completion of the share issue, Lund University Bioscience AB owns a total of 2 320 370 shares.

For further information, please contact:
Jan Alenfall - CEO, Follicum AB
Telephone: 046 - 19 21 97
E-mail: info@follicum.com 

About Follicum AB
Follicum AB is a biotechnology company focusing on research and development of peptide-based drugs. Follicum´s primary focus is the stimulation of hair growth, where the company has recently completed a clinical trial with very promising results for the candidate product FOL-005. In diabetes, the drug candidate FOL-014 has been demonstrated an increase in the release of insulin in pre-clinical models. The company was founded in 2011 and is based in Lund, Sweden. Follicum has been listed on AktieTorget, the Swedish small cap stock exchange, since 2014 and is publically traded under the stock symbol: FOLLI.  www.follicum.com


About Us

Follicum AB (publ) develops drug candidates based on tissue reparing peptides with potential use in several therapeutic areas. The company’s primary candidate, FOL-005 for stimulating hair growth, is currently being evaluated in a phase IIa study in collaboration with internationally reputable specialist clinics. The company’s project in diabetes aims at protecting insulin producing cells against damage and thereby reducing the risk of complications. Based on promising preclinical results preparations for entering a phase I study is ongoing, which expects to be initiated in 2021. Both projects have the potential of becoming so called first-in-class drugs. For more information, please visit www.follicum.com.


Documents & Links